Home Primary Antibodies Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22]

research use only

Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22]

Cat.No.: F2359

    Application: Reactivity:
    • F2359-wb
      Lane 1: PC12, Lane 2: PC12 (nerve growth factor-β, 100ng/ml, 5 min), Lane 3: PC12 (nerve growth factor-β, 100ng/ml, 5 min; phosphatase treated), Lane 4: Mouse brain

    Usage Information

    Dilution
    1:500-1:2000
    1:40
    1:50
    Application
    WB, IP, IHC
    Reactivity
    Rat, Human, Zebrafish, Mouse
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    50 kDa 47-52 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.
    Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

    Datasheet & SDS

    Biological Description

    Specificity
    Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22] detects endogenous levels of total GSK3β and GSK3α protein only when it is phosphorylated at Y216 and Y279 respectively.
    Clone
    F22P22
    Synonym(s)
    Glycogen synthase kinase-3 beta/alpha; GSK3B; GSK3A
    Background
    Phosphorylated GSK3β (Y216) and GSK3α (Y279) denote activation‑loop tyrosine phosphorylation events on the two closely related glycogen synthase kinase 3 isoforms, which are constitutively active serine/threonine kinases that regulate multiple signaling cascades in the brain, liver, and other tissues. GSK3α and GSK3β both contain an N‑terminal kinase domain with a T‑loop whose phosphorylation at Y279 and Y216, respectively, stabilizes an open, active conformation that enhances substrate recognition and phosphotransfer to key effectors such as β‑catenin, glycogen synthase, and Tau. In the Wnt/β‑catenin pathway, active GSK3α and GSK3β phosphorylate β‑catenin within the destruction complex, promoting its ubiquitination and proteasomal degradation unless upstream Wnt ligands inhibit the complex through Dishevelled‑ and Axin‑dependent mechanisms, whereas in the insulin/PI3K/Akt axis Akt‑dependent inhibitory phosphorylation at Ser21 in GSK3α and Ser9 in GSK3β acts as a negative feedback node that dampens GSK3 activity and licenses glycogen synthase activation and normalized glucose metabolism. Phospho‑GSK3β (Y216)‑enriched states correlate with increased phosphorylation of Tau at multiple sites, contributing to Tau misfolding, tangle‑like assembly, and synaptic dysfunction in Alzheimer’s disease, while in metabolic tissues elevated GSK3β (Y216) phosphorylation is associated with impaired insulin signaling through IRS1, reduced glycogen synthesis, and dysglycemia in diabetes mellitus.
    References
    • https://pubmed.ncbi.nlm.nih.gov/31057171/
    • https://pubmed.ncbi.nlm.nih.gov/38882600/

    Tech Support

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3

    If you have any other enquiries, please leave a message.